• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and safety of ticagrelor versus clopidogrel with different dosages in acute coronary syndrome patients with high GRACE and CRUSADE scores
CONCLUSIONS: In PCI patients with a high ischemic and bleeding risk, the ticagrelor antiplatelet strategy significantly reduced the MACCE rate without increasing the risk of major bleeding. A decreased MACCE rate was also observed in patients administered the double dosage of clopidogrel, but the bleeding risk was increased compared with the control group.PMID:34154742 | PMC:PMC8322751 | DOI:10.1016/j.ihj.2021.02.002
Source: Indian Heart J - June 22, 2021 Category: Cardiology Authors: Peng Xiao Feng Xie Yunjing Lan Source Type: research

Clopidogrel Monotherapy in Patients with and without On-Treatment High Platelet Reactivity: a SMART-CHOICE sub-study
CONCLUSIONS: Clopidogrel monotherapy showed treatment effects comparable to DAPT for MACCE in patients with or without HPR. However, HPR was significantly associated with an increased risk of MACCE in clopidogrel-treated patients regardless of maintenance of aspirin.PMID:34031020 | DOI:10.4244/EIJ-D-21-00223
Source: EuroIntervention - May 25, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Seung Hun Lee Sang Yeub Lee Woo Jung Chun Young Bin Song Seung-Hyuk Choi Jin-Ok Jeong Seok Kyu Oh Kyeong Ho Yun Young-Youp Koh Jang-Whan Bae Jae Woong Choi Hyeon-Cheol Gwon Joo-Yong Hahn Source Type: research

Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
Abstract: Dual antiplatelet treatment, consisting of aspirin and P2Y12 inhibitors, is essential for diabetes mellitus (DM) patients who have undergone percutaneous coronary intervention (PCI). This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI. PubMed, the Cochrane Library and Google Scholar were searched for randomized controlled trials in which ticagrelor was administered. Eligible studies were independently scrutinized to extract data and assess the trials' quality. Statistical analysis was perfo...
Source: Journal of Cardiovascular Pharmacology - May 1, 2021 Category: Cardiology Tags: Review Article Source Type: research

Serum Free Triiodothyronine and the Responsiveness to Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention
ConclusionsLow FT3 was independently associated with increased risks of both low responsiveness to clopidogrel and cardiovascular events in patients undergoing elective PCI.
Source: Advances in Therapy - April 29, 2021 Category: Drugs & Pharmacology Source Type: research

Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
CONCLUSION: Compared with prolonged DAPT, clopidogrel monotherapy showed similar long-term outcomes in patients at high-risk after second-generation DES implantation.PMID:33904262 | DOI:10.3346/jkms.2021.36.e106
Source: Journal of Korean Medical Science - April 27, 2021 Category: Biomedical Science Authors: Dong Yeon Kim Sung Woo Cho Kyu Tae Park Jong Hwa Ahn Taek Kyu Park Yong Ho Jang Ki Hong Choi Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin Ho Choi Seung Hyuk Choi Hyeon Cheol Gwon Sang Hoon Lee Joo Yong Hahn Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20